Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Plus Therapeutics (PSTV) Gross Margin (2016 - 2019)

Plus Therapeutics (PSTV) has disclosed Gross Margin for 9 consecutive years, with 83.78% as the latest value for Q1 2019.

  • On a quarterly basis, Gross Margin rose 6299.0% to 83.78% in Q1 2019 year-over-year; TTM through Mar 2019 was 61.05%, a 4606.0% increase, with the full-year FY2018 number at 82.48%, up 7705.0% from a year prior.
  • Gross Margin was 83.78% for Q1 2019 at Plus Therapeutics, down from 96.69% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 96.69% in Q4 2018 to a low of 21.15% in Q1 2017.
  • A 5-year average of 31.32% and a median of 27.04% in 2017 define the central range for Gross Margin.
  • Peak YoY movement for Gross Margin: crashed -7861bps in 2017, then skyrocketed 9216bps in 2018.
  • Plus Therapeutics' Gross Margin stood at 49.16% in 2015, then fell by -28bps to 35.54% in 2016, then tumbled by -87bps to 4.53% in 2017, then skyrocketed by 2034bps to 96.69% in 2018, then fell by -13bps to 83.78% in 2019.
  • Per Business Quant, the three most recent readings for PSTV's Gross Margin are 83.78% (Q1 2019), 96.69% (Q4 2018), and 26.81% (Q3 2018).